REGULUS THERAPEUTICS INC. overview

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates PR Newswire SAN DIEGO, March 21, 2024 Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Oversubscribed $100 million private placement; expected to extend cash runway into H1 2026 Completed enrollment of the third cohort of patients in the MAD study;...

Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew? PR Newswire NEW YORK, March 12, 2024 NEW YORK , March 12, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBAI, NUKK, SGLY, RGLS, and RERE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. BBAI:...

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, March 12, 2024 Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the...

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity PR Newswire SAN DIEGO, March 12, 2024 SAN DIEGO , March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional...

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, Jan. 2, 2024 SAN DIEGO , Jan. 2, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today...

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire SAN DIEGO, Nov. 22, 2023 SAN DIEGO , Nov. 22, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan will be participating in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday November...

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates PR Newswire SAN DIEGO, Nov. 9, 2023 Announced positive topline data from the first cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed enrollment in the second cohort of the Phase 1b MAD Clinical Trial of RGLS8429 for the Treatment of ADPKD First patient dosed in the third cohort of the Phase...

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO, Nov. 2, 2023 SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the dosing...